Loading...

Operating Data

Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. (APVO)

Healthcare

Year
A/P
2014
Actual
2015
Actual
2016
Actual
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Revenue 45.6333.6036.4414.6623.0721.9020.7819.7318.7317.77
Revenue (%)
EBITDA -49.69-58.43-123.58-50.82-49.27-51.77-49.14-46.65-44.28-42.03
EBITDA (%)
EBIT -51.71-61.34-126.94-53.95-51.66-54.14-51.39-48.78-46.30-43.95
EBIT (%)
Depreciation 2.022.913.363.132.392.362.242.132.021.92
Depreciation (%)




EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT)
EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income)
EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization
EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company
(1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments),
(2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill)
(3*) collections of assets (by ignoring depreciation of assets)
(4*) different takeover histories (by ignoring amortization often stemming from goodwill)